Selected research
Market Outlook & Growth Opportunities
Global Ceftazidime Market Outlook and Growth Opportunities 2026
Market perspective
The global Ceftazidime market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Ceftazidime is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Ceftazidime is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Ceftazidime is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Ceftazidime market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Ceftazidime market include Fujian Fukang Pharmaceutical, NCPC, United Laboratories, Sinopharm Sandwich, Shanghai Pharmaceutical, Union Chempharma and Youcare Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Ceftazidime market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Ceftazidime and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Ceftazidime sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ceftazidime market size, projected growth trends, production technologies, key applications, and end-use industries.
Ceftazidime Segment by Company
Fujian Fukang Pharmaceutical
NCPC
United Laboratories
Sinopharm Sandwich
Shanghai Pharmaceutical
Union Chempharma
Youcare Pharmaceutical
Ceftazidime Segment by Type
Powder Injection
Injection
Ceftazidime Segment by Application
Respiratory Infections
Urinary Infections
Skin Infections
Other
Ceftazidime Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Ceftazidime status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Ceftazidime market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ceftazidime significant trends, drivers, influence factors in global and regions.
6. To analyze Ceftazidime competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ceftazidime market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ceftazidime and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ceftazidime.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Ceftazidime market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ceftazidime industry.
Chapter 3: Detailed analysis of Ceftazidime manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Ceftazidime in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Ceftazidime in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Powder Injection
- Injection
Applications
- Respiratory Infections
- Urinary Infections
- Skin Infections
- Other
Companies covered
- Fujian Fukang Pharmaceutical
- NCPC
- United Laboratories
- Sinopharm Sandwich
- Shanghai Pharmaceutical
- Union Chempharma
- Youcare Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Ceftazidime Sales Value (2021-2032)
- 1.2.2 Global Ceftazidime Sales Volume (2021-2032)
- 1.2.3 Global Ceftazidime Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Ceftazidime Market Dynamics
- 2.1 Ceftazidime Industry Trends
- 2.2 Ceftazidime Industry Drivers
- 2.3 Ceftazidime Industry Opportunities and Challenges
- 2.4 Ceftazidime Industry Restraints
3 Ceftazidime Market by Company
- 3.1 Global Ceftazidime Company Revenue Ranking in 2025
- 3.2 Global Ceftazidime Revenue by Company (2021-2026)
- 3.3 Global Ceftazidime Sales Volume by Company (2021-2026)
- 3.4 Global Ceftazidime Average Price by Company (2021-2026)
- 3.5 Global Ceftazidime Company Ranking (2024-2026)
- 3.6 Global Ceftazidime Company Manufacturing Base and Headquarters
- 3.7 Global Ceftazidime Company Product Type and Application
- 3.8 Global Ceftazidime Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Ceftazidime Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Ceftazidime Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Ceftazidime Market by Type
- 4.1 Ceftazidime Type Introduction
- 4.1.1 Powder Injection
- 4.1.2 Injection
- 4.2 Global Ceftazidime Sales Volume by Type
- 4.2.1 Global Ceftazidime Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Ceftazidime Sales Volume by Type (2021-2032)
- 4.2.3 Global Ceftazidime Sales Volume Share by Type (2021-2032)
- 4.3 Global Ceftazidime Sales Value by Type
- 4.3.1 Global Ceftazidime Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Ceftazidime Sales Value by Type (2021-2032)
- 4.3.3 Global Ceftazidime Sales Value Share by Type (2021-2032)
5 Ceftazidime Market by Application
- 5.1 Ceftazidime Application Introduction
- 5.1.1 Respiratory Infections
- 5.1.2 Urinary Infections
- 5.1.3 Skin Infections
- 5.1.4 Other
- 5.2 Global Ceftazidime Sales Volume by Application
- 5.2.1 Global Ceftazidime Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Ceftazidime Sales Volume by Application (2021-2032)
- 5.2.3 Global Ceftazidime Sales Volume Share by Application (2021-2032)
- 5.3 Global Ceftazidime Sales Value by Application
- 5.3.1 Global Ceftazidime Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Ceftazidime Sales Value by Application (2021-2032)
- 5.3.3 Global Ceftazidime Sales Value Share by Application (2021-2032)
6 Ceftazidime Regional Sales and Value Analysis
- 6.1 Global Ceftazidime Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Ceftazidime Sales by Region (2021-2032)
- 6.2.1 Global Ceftazidime Sales by Region: 2021-2026
- 6.2.2 Global Ceftazidime Sales by Region (2027-2032)
- 6.3 Global Ceftazidime Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Ceftazidime Sales Value by Region (2021-2032)
- 6.4.1 Global Ceftazidime Sales Value by Region: 2021-2026
- 6.4.2 Global Ceftazidime Sales Value by Region (2027-2032)
- 6.5 Global Ceftazidime Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Ceftazidime Sales Value (2021-2032)
- 6.6.2 North America Ceftazidime Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Ceftazidime Sales Value (2021-2032)
- 6.7.2 Europe Ceftazidime Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Ceftazidime Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Ceftazidime Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Ceftazidime Sales Value (2021-2032)
- 6.9.2 South America Ceftazidime Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Ceftazidime Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Ceftazidime Sales Value Share by Country, 2025 VS 2032
7 Ceftazidime Country-level Sales and Value Analysis
- 7.1 Global Ceftazidime Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Ceftazidime Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Ceftazidime Sales by Country (2021-2032)
- 7.3.1 Global Ceftazidime Sales by Country (2021-2026)
- 7.3.2 Global Ceftazidime Sales by Country (2027-2032)
- 7.4 Global Ceftazidime Sales Value by Country (2021-2032)
- 7.4.1 Global Ceftazidime Sales Value by Country (2021-2026)
- 7.4.2 Global Ceftazidime Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.9.2 France Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.16.2 China Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.19.2 India Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Ceftazidime Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Ceftazidime Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Ceftazidime Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Ceftazidime Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Fujian Fukang Pharmaceutical
- 8.1.1 Fujian Fukang Pharmaceutical Company Information
- 8.1.2 Fujian Fukang Pharmaceutical Business Overview
- 8.1.3 Fujian Fukang Pharmaceutical Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Fujian Fukang Pharmaceutical Ceftazidime Product Portfolio
- 8.1.5 Fujian Fukang Pharmaceutical Recent Developments
- 8.2 NCPC
- 8.2.1 NCPC Company Information
- 8.2.2 NCPC Business Overview
- 8.2.3 NCPC Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.2.4 NCPC Ceftazidime Product Portfolio
- 8.2.5 NCPC Recent Developments
- 8.3 United Laboratories
- 8.3.1 United Laboratories Company Information
- 8.3.2 United Laboratories Business Overview
- 8.3.3 United Laboratories Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.3.4 United Laboratories Ceftazidime Product Portfolio
- 8.3.5 United Laboratories Recent Developments
- 8.4 Sinopharm Sandwich
- 8.4.1 Sinopharm Sandwich Company Information
- 8.4.2 Sinopharm Sandwich Business Overview
- 8.4.3 Sinopharm Sandwich Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Sinopharm Sandwich Ceftazidime Product Portfolio
- 8.4.5 Sinopharm Sandwich Recent Developments
- 8.5 Shanghai Pharmaceutical
- 8.5.1 Shanghai Pharmaceutical Company Information
- 8.5.2 Shanghai Pharmaceutical Business Overview
- 8.5.3 Shanghai Pharmaceutical Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Shanghai Pharmaceutical Ceftazidime Product Portfolio
- 8.5.5 Shanghai Pharmaceutical Recent Developments
- 8.6 Union Chempharma
- 8.6.1 Union Chempharma Company Information
- 8.6.2 Union Chempharma Business Overview
- 8.6.3 Union Chempharma Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Union Chempharma Ceftazidime Product Portfolio
- 8.6.5 Union Chempharma Recent Developments
- 8.7 Youcare Pharmaceutical
- 8.7.1 Youcare Pharmaceutical Company Information
- 8.7.2 Youcare Pharmaceutical Business Overview
- 8.7.3 Youcare Pharmaceutical Ceftazidime Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Youcare Pharmaceutical Ceftazidime Product Portfolio
- 8.7.5 Youcare Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Ceftazidime Value Chain Analysis
- 9.1.1 Ceftazidime Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Ceftazidime Sales Mode & Process
- 9.2 Ceftazidime Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Ceftazidime Distributors
- 9.2.3 Ceftazidime Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst